, meta-analyses, randomized clinical trials, and through models of cost efÔ¨Åcacy.
In an early institutional series, 45 patients with symptomatic carotid stenoses who were considered high risk (NASCET-ineligible) for CEA underwent CAS between 1996 and
2002, and their costs were compared with a control series
of 391 patients with comparable risk factors who underwent CEA. Median total costs were $1